JP2004520031A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004520031A5 JP2004520031A5 JP2002555832A JP2002555832A JP2004520031A5 JP 2004520031 A5 JP2004520031 A5 JP 2004520031A5 JP 2002555832 A JP2002555832 A JP 2002555832A JP 2002555832 A JP2002555832 A JP 2002555832A JP 2004520031 A5 JP2004520031 A5 JP 2004520031A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- fusion protein
- acid construct
- pharmaceutically active
- mmp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000007523 nucleic acids Chemical group 0.000 claims 18
- 108010000684 Matrix Metalloproteinases Proteins 0.000 claims 16
- 102000002274 Matrix Metalloproteinases Human genes 0.000 claims 16
- 102000037865 fusion proteins Human genes 0.000 claims 16
- 108020001507 fusion proteins Proteins 0.000 claims 16
- 108020004707 nucleic acids Proteins 0.000 claims 12
- 102000039446 nucleic acids Human genes 0.000 claims 12
- 102000004169 proteins and genes Human genes 0.000 claims 11
- 108090000623 proteins and genes Proteins 0.000 claims 11
- 102000004127 Cytokines Human genes 0.000 claims 7
- 108090000695 Cytokines Proteins 0.000 claims 7
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 6
- 230000006337 proteolytic cleavage Effects 0.000 claims 6
- 102000004190 Enzymes Human genes 0.000 claims 4
- 108090000790 Enzymes Proteins 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 201000001320 Atherosclerosis Diseases 0.000 claims 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 206010039710 Scleroderma Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 208000027866 inflammatory disease Diseases 0.000 claims 3
- 208000017169 kidney disease Diseases 0.000 claims 3
- 201000006417 multiple sclerosis Diseases 0.000 claims 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 3
- 102100026802 72 kDa type IV collagenase Human genes 0.000 claims 2
- 102000019034 Chemokines Human genes 0.000 claims 2
- 108010012236 Chemokines Proteins 0.000 claims 2
- 229940123457 Free radical scavenger Drugs 0.000 claims 2
- 101000627872 Homo sapiens 72 kDa type IV collagenase Proteins 0.000 claims 2
- 101001013150 Homo sapiens Interstitial collagenase Proteins 0.000 claims 2
- 101000990912 Homo sapiens Matrilysin Proteins 0.000 claims 2
- 101000990902 Homo sapiens Matrix metalloproteinase-9 Proteins 0.000 claims 2
- 101000990908 Homo sapiens Neutrophil collagenase Proteins 0.000 claims 2
- 101000990915 Homo sapiens Stromelysin-1 Proteins 0.000 claims 2
- 101000577874 Homo sapiens Stromelysin-2 Proteins 0.000 claims 2
- 102000014150 Interferons Human genes 0.000 claims 2
- 108010050904 Interferons Proteins 0.000 claims 2
- 102000015696 Interleukins Human genes 0.000 claims 2
- 108010063738 Interleukins Proteins 0.000 claims 2
- 102100030417 Matrilysin Human genes 0.000 claims 2
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 claims 2
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 claims 2
- 102000005741 Metalloproteases Human genes 0.000 claims 2
- 108010006035 Metalloproteases Proteins 0.000 claims 2
- 102100030411 Neutrophil collagenase Human genes 0.000 claims 2
- 229940122055 Serine protease inhibitor Drugs 0.000 claims 2
- 101710102218 Serine protease inhibitor Proteins 0.000 claims 2
- 102100030416 Stromelysin-1 Human genes 0.000 claims 2
- 102100028848 Stromelysin-2 Human genes 0.000 claims 2
- 238000003776 cleavage reaction Methods 0.000 claims 2
- 102000003675 cytokine receptors Human genes 0.000 claims 2
- 108010057085 cytokine receptors Proteins 0.000 claims 2
- 230000004069 differentiation Effects 0.000 claims 2
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 239000003102 growth factor Substances 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 229940079322 interferon Drugs 0.000 claims 2
- 235000015097 nutrients Nutrition 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims 2
- 239000000816 peptidomimetic Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000000651 prodrug Substances 0.000 claims 2
- 229940002612 prodrug Drugs 0.000 claims 2
- 239000002516 radical scavenger Substances 0.000 claims 2
- 230000007017 scission Effects 0.000 claims 2
- 239000003001 serine protease inhibitor Substances 0.000 claims 2
- 102000008121 Latent TGF-beta Binding Proteins Human genes 0.000 claims 1
- 108010049807 Latent TGF-beta Binding Proteins Proteins 0.000 claims 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 238000010382 chemical cross-linking Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 238000000746 purification Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/756,283 US6942853B2 (en) | 2001-01-09 | 2001-01-09 | Latent fusion protein |
| GBGB0100551.1A GB0100551D0 (en) | 2001-01-09 | 2001-01-09 | Protein |
| PCT/GB2002/000068 WO2002055098A2 (en) | 2001-01-09 | 2002-01-09 | Latency associated peptide for providing latency to pharmaceutically active proteins |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004520031A JP2004520031A (ja) | 2004-07-08 |
| JP2004520031A5 true JP2004520031A5 (https=) | 2005-12-22 |
| JP4201253B2 JP4201253B2 (ja) | 2008-12-24 |
Family
ID=26245544
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002555832A Expired - Fee Related JP4201253B2 (ja) | 2001-01-09 | 2002-01-09 | 薬学的活性物質に潜在性を提供する方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US6942853B2 (https=) |
| EP (1) | EP1349944B1 (https=) |
| JP (1) | JP4201253B2 (https=) |
| AT (1) | ATE293169T1 (https=) |
| AU (1) | AU2002219345B2 (https=) |
| DE (1) | DE60203692T2 (https=) |
| DK (1) | DK1349944T3 (https=) |
| ES (1) | ES2240740T3 (https=) |
| GB (1) | GB0100551D0 (https=) |
| WO (1) | WO2002055098A2 (https=) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7141392B2 (en) * | 2001-01-09 | 2006-11-28 | Queen Mary And Westfield College | Latent fusion protein |
| US20030219402A1 (en) * | 2002-02-14 | 2003-11-27 | Rutter William J. | Chimeric molecules for cleavage in a treated host |
| JP2009510166A (ja) * | 2005-10-04 | 2009-03-12 | グリーンビル ホスピタル システム | 潜伏性プロサイトトキシンおよびそれらの用途 |
| DE102006009324A1 (de) | 2006-03-01 | 2007-09-06 | Dr.Ing.H.C. F. Porsche Ag | Verfahren und Steuergerät zur Steuerung eines variablen Turbolader-Turbinenströmungsquerschnitts |
| WO2008130382A2 (en) | 2006-10-31 | 2008-10-30 | East Carolina University | Fusion proteins comprising an anti -inflammatory cytokine and an antigen for treatment of immune disorders |
| GB0724556D0 (en) * | 2007-12-17 | 2008-01-30 | Queen Mary & Westfield College | LAtency associated protein construct with aggrecanase sensitive cleavage site |
| FR2932190A1 (fr) * | 2008-06-10 | 2009-12-11 | Commissariat Energie Atomique | Peptides cycliques fluorescents, procedes de preparation de ceux-ci et utilisation de ces peptides pour mesurer l'activite enzymatique d'une enzyme protease |
| CA2757287C (en) | 2009-03-31 | 2019-09-10 | East Carolina University | Cytokines and neuroantigens for treatment of immune disorders |
| GB0911365D0 (en) | 2009-06-30 | 2009-08-12 | Bioceramic Therapeutics Ltd | Multicomponent glasses for use as coatings and in personal care products |
| EP2553101A4 (en) * | 2010-04-02 | 2013-09-04 | Univ Rochester | PROTEASE-ACTIVATED CYTOKINES |
| EP2878308B1 (en) * | 2013-12-02 | 2018-10-31 | Thomas Harder | Agents and methods for the suppression of T cell activation |
| GB201411506D0 (en) * | 2014-06-27 | 2014-08-13 | Univ London Queen Mary | Modified latency associated protein construct |
| JP6516235B2 (ja) * | 2014-10-31 | 2019-05-22 | 国立大学法人富山大学 | キメラタンパク質及びそれを用いたミクログリア活性阻害剤 |
| CA3100005A1 (en) | 2018-05-14 | 2019-11-21 | Werewolf Therapeutics, Inc. | Activatable cytokine polypeptides and methods of use thereof |
| AU2019271148B9 (en) | 2018-05-14 | 2025-05-29 | Werewolf Therapeutics, Inc. | Activatable interleukin-2 polypeptides and methods of use thereof |
| US12459980B2 (en) | 2018-07-25 | 2025-11-04 | AskGene Pharma, Inc. | IL-21 prodrugs and methods of use thereof |
| CN120463822A (zh) * | 2018-09-27 | 2025-08-12 | 西里欧发展公司 | 掩蔽型细胞因子多肽 |
| ES2780274A1 (es) * | 2019-02-15 | 2020-08-24 | Consejo Superior De Investig Científicas (Csic) | Cortistatina o un análogo de la misma como agente farmacéuticamente activo en forma latente |
| KR20220023988A (ko) | 2019-05-14 | 2022-03-03 | 웨어울프 세라퓨틱스, 인크. | 분리 모이어티 및 이의 사용 방법 |
| KR20220020879A (ko) | 2019-06-12 | 2022-02-21 | 에스크진 파마, 아이엔씨. | 새로운 il-15 프로드럭 및 이를 사용하는 방법 |
| BR112022009110A2 (pt) | 2019-11-14 | 2022-07-26 | Werewolf Therapeutics Inc | Polipeptídeos de citocina ativáveis e métodos de uso destes |
| WO2021142471A1 (en) | 2020-01-11 | 2021-07-15 | AskGene Pharma, Inc. | Novel masked cytokines and methods of use thereof |
| GB202004679D0 (en) | 2020-03-31 | 2020-05-13 | Stealthyx Therapeutics Ltd | Modified latercy associated protein construct |
| AU2021254283B2 (en) * | 2020-04-10 | 2025-12-11 | Cytomx Therapeutics, Inc. | Activatable cytokine constructs and related compositions and methods |
| WO2022115865A2 (en) | 2020-11-25 | 2022-06-02 | Xilio Development, Inc. | Tumor-specific cleavable linkers |
| JP2024511387A (ja) | 2021-03-16 | 2024-03-13 | シートムエックス セラピューティクス，インコーポレイテッド | マスクした活性化可能サイトカイン構成体ならびに関連する組成物及び方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5284763A (en) | 1985-03-22 | 1994-02-08 | Genentech, Inc. | Nucleic acid encoding TGF-β and its uses |
| CA2003886A1 (en) | 1988-12-16 | 1990-06-16 | Anthony F. Purchio | Cloning and expression of simian transforming growth factor-beta 1 |
| ES2083469T3 (es) | 1989-11-22 | 1996-04-16 | Genentech Inc | Peptido asociado a una latencia y utilizaciones del mismo. |
| US5697901A (en) | 1989-12-14 | 1997-12-16 | Elof Eriksson | Gene delivery by microneedle injection |
| BR9406715A (pt) | 1993-05-12 | 1996-02-06 | Genetics Inst | Molécula de DNA isolada célula hospedeira vetor método para produzir uma proteina (BMP-11) polipeptideo de proteina-11 morfogenética de osso purificada (BMP-11) e molécula de DNA quimérica |
| CA2712304C (en) | 1994-06-10 | 2011-10-25 | United States Surgical Corporation | Recombinant chimeric proteins and methods of use thereof |
| US5800811A (en) * | 1995-06-06 | 1998-09-01 | Hall; Frederick L. | Artificial skin prepared from coclagen matrix containing transforming growth factor-β having a collagen binding site |
| CA2232669A1 (en) * | 1995-09-27 | 1997-04-03 | Frances Joanne Morling | Recombinant viruses incorporating a protease cleavable protein |
| DE19701141C1 (de) | 1997-01-16 | 1998-04-09 | Hoechst Ag | Genkonstrukte für durch Proteasen aktivierbare Wirksubstanzen |
| US6593132B1 (en) * | 1997-04-30 | 2003-07-15 | Twinstrand Therapeutics Inc. | Ricin-like toxin variants for treatment of cancer, viral or parasitic infections |
| GB2324960A (en) | 1997-05-09 | 1998-11-11 | Univ Manchester | Delivery of naked DNA for wound healing |
| JP3762222B2 (ja) | 1998-10-07 | 2006-04-05 | ストライカー・コーポレーション | 改変型ＴＧＦ−βスーパーファミリータンパク質 |
| JP2004508838A (ja) * | 2000-09-11 | 2004-03-25 | ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク | 組合せ蛍光エネルギー移動タグ及びそれらの使用 |
-
2001
- 2001-01-09 US US09/756,283 patent/US6942853B2/en not_active Expired - Lifetime
- 2001-01-09 GB GBGB0100551.1A patent/GB0100551D0/en not_active Ceased
-
2002
- 2002-01-09 WO PCT/GB2002/000068 patent/WO2002055098A2/en not_active Ceased
- 2002-01-09 ES ES02729440T patent/ES2240740T3/es not_active Expired - Lifetime
- 2002-01-09 JP JP2002555832A patent/JP4201253B2/ja not_active Expired - Fee Related
- 2002-01-09 AU AU2002219345A patent/AU2002219345B2/en not_active Ceased
- 2002-01-09 EP EP02729440A patent/EP1349944B1/en not_active Expired - Lifetime
- 2002-01-09 AT AT02729440T patent/ATE293169T1/de not_active IP Right Cessation
- 2002-01-09 DE DE60203692T patent/DE60203692T2/de not_active Expired - Lifetime
- 2002-01-09 DK DK02729440T patent/DK1349944T3/da active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004520031A5 (https=) | ||
| Le et al. | The dual personalities of matrix metalloproteinases in inflammation | |
| Pérez-García et al. | Profile of matrix-remodeling proteinases in osteoarthritis: impact of fibronectin | |
| Van Lint et al. | Chemokine and cytokine processing by matrix metalloproteinases and its effect on leukocyte migration and inflammation | |
| Rengel et al. | Proteinases in the joint: clinical relevance of proteinases in joint destruction | |
| Cawston et al. | Proteinases involved in matrix turnover during cartilage and bone breakdown | |
| Murphy | Matrix metalloproteinases and their inhibitors | |
| Birkedal‐Hansen | Role of cytokines and inflammatory mediators in tissue destruction | |
| Uchida et al. | Regulation of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) by bone resorptive factors in osteoblastic cells | |
| Cudic et al. | Extracellular proteases as targets for drug development | |
| Song et al. | Matrix metalloproteinase dependent and independent collagen degradation | |
| Fibbe et al. | The role of metalloproteinases and adhesion molecules in interleukin-8-induced stem-cell mobilization | |
| FI3794024T3 (fi) | Aktivoitavia interleukiini-2-polypeptidejä ja niiden käyttömenetelmiä | |
| Djuric et al. | Overview of MMP Biology and Gene Associations in | |
| DK1349944T3 (da) | Latensassocieret peptid af TGF-beta til at bibringe farmaceutisk aktive proteiner latens | |
| Cawston et al. | Matrix metalloproteinases and TIMPs: properties and implications for the treatment of chronic obstructive pulmonary disease | |
| ES2203088T3 (es) | Nuevos inhibidores y reguladores negativos de metaloproteinasas de matriz. | |
| Demers et al. | New roles for matrix metalloproteinases in metastasis | |
| NAKAGAWA et al. | Changes in the levels of rat interleukin 8/CINC and gelatinase in the exudate of carrageenin-induced inflammation in rats | |
| Yoshimura et al. | Transcriptional and posttranscriptional modulation of human neutrophil elastase gene expression | |
| US20130149295A1 (en) | Furin and biologically active derivatives thereof for use in the prevention or treatment of an inflammatory disease | |
| Cox et al. | Cytokine substrates: MMP regulation of inflammatory signaling molecules | |
| CN106496329B (zh) | 一种含有胶原蛋白结合结构域的融合蛋白 | |
| AR039021A1 (es) | Gen humano de la proteasa desubiquitinante del cromosoma 7 y su ortologo murino | |
| Müller-Ladner et al. | Signaling and effector pathways |